Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
August 20, 2026British Journal of HaematologyOpen Access

Salvage treatment patterns in multiple myeloma patients progressing after lenalidomide maintenance: A real‐life study from European Myeloma Network ( EMN ) Italy

View Full Paper
Ask AI
Bookmark
Share

Authors

GBGregorio BarilàAGAngela GrassiVRValeria Ruocco

Discussion

Loading...

Member takes

Overview

Cohort study reveals improved survival with anti-CD38 regimens in multiple myeloma relapsing on lenalidomide maintenance, highlighting isatuximab-carfilzomib-dexamethasone as an effective salvage...

Key Points

  • Evaluate the real-world effectiveness of salvage regimens in multiple myeloma patients who experience disease progression during lenalidomide maintenance following autologous haematopoietic stem cell transplantation.
  • Analyzed a real-life cohort of N=306 patients in Italy who relapsed during lenalidomide maintenance after autologous haematopoietic stem cell transplantation (AHSCT).
  • Evaluated progression-free survival (PFS) and overall survival (OS) across various licensed salvage treatments, primarily anti-CD38 monoclonal antibody-based regimens.
  • The most common salvage regimens were Isa-KD (45.4%), D-PD (19.3%), and D-VD (12.4%), with anti-CD38 antibody-based regimens showing improved survival and Isa-KD achieving the longest PFS at 22.8 months.
  • PFS and OS were significantly reduced in patients with high LDH (p = 0.0003 and p < 0.0001), ISS stage ≥2 (p < 0.0001 and p < 0.0001), and early relapse within 12 months of maintenance initiation (p = 0.0017 and p = 0.0009).

Cite This Study

Barilà et al. (2026) studied this question.

synapsesocial.com/papers/6a86b5b08a91293e6a1cd349https://doi.org/10.1111/bjh.70751
View Full Paper
Ask AI
Bookmark
Share